Introduction
Human Tetanus Immunoglobulin (HTIG) is a preparation of pooled human immunoglobulins that contains antibodies against tetanus toxin. It is used as a passive immunization to prevent or treat tetanus infections in individuals who have been exposed to the tetanus bacterium or who are at high risk of tetanus.
Uses
Human Tetanus Immunoglobulin is used for:
- Post-exposure prophylaxis in individuals who have not been adequately vaccinated against tetanus or whose vaccination status is unknown, especially after a tetanus-prone wound.
- Treatment of tetanus infection, in conjunction with tetanus toxoid vaccination and appropriate wound management.
- Providing immediate but temporary immunity in cases where active immunization with tetanus toxoid is not possible.
| Brand Name | Human Tetanus Immunoglobulin |
|---|---|
| Type | |
| Weight | |
| Generic | Human Tetanus Immunoglobulin |
| Manufacturer | |
| Available in | English বাংলা |
Mechanism of Action
Human Tetanus Immunoglobulin provides passive immunity by supplying antibodies against the tetanus toxin. These antibodies neutralize the toxin and prevent its binding to nerve endings, thus preventing the progression of tetanus and aiding in the resolution of the infection.
How Long Does It Take to Work?
The effects of Human Tetanus Immunoglobulin are typically immediate, providing prompt protection against the tetanus toxin. However, it is used in conjunction with tetanus toxoid to provide long-term immunity.
Absorption
Human Tetanus Immunoglobulin is administered intramuscularly, and its components are rapidly absorbed into the bloodstream.
Route of Elimination
The antibodies in Human Tetanus Immunoglobulin are gradually broken down by the body, with their elimination primarily occurring through the reticuloendothelial system. The half-life of these immunoglobulins varies but is generally around 2-3 weeks.
Dosage
Post-exposure prophylaxis of tetanus:- For adults and children single dose of 250 IU should be given. The dose may be increased to 500 IU in case of:
- Infected wounds where surgically appropriate treatment cannot be achieved within 24 hours
- Deep or contaminated wounds with tissue damage and reduced oxygen supply, as well as foreign body injury (e.g., bites, stings or shots)
- Burns, congelations
- Tissue necrosis
- Septicaemic abortion
- Adults weighing more than the average
At the same time, 0.5 ml of tetanus vaccine in a different extremity with a separate syringe and complete immunization schedule is required to be administered.
Therapy of clinically manifest tetanus: For adults and children single doses of 3,000 to 6,000 IU (in combination with other appropriate clinical procedures).
The dosage of Human Tetanus Immunoglobulin depends on the clinical situation and the patient's exposure history:
- For post-exposure prophylaxis: Typically, 250 units administered intramuscularly as a single dose.
- For treatment of tetanus: Dosage may be higher and is tailored to the severity of the infection and patient needs.
Administration
Human Tetanus Immunoglobulin is administered intramuscularly, usually in the deltoid muscle. It should be given as soon as possible after exposure to tetanus or in the presence of a tetanus-prone wound.
Side Effects
Common side effects may include:
- Local reactions at the injection site, such as pain, swelling, or redness.
- Mild fever.
- Allergic reactions, though rare.
Toxicity
Human Tetanus Immunoglobulin is generally well-tolerated. Toxicity is rare but may include severe allergic reactions or anaphylaxis. In such cases, immediate medical attention is required.
Precautions
Precautions include:
- Monitor for allergic reactions, especially in patients with a history of hypersensitivity to immunoglobulins.
- Use with caution in patients with a history of severe adverse reactions to previous doses of immunoglobulins.
Interaction
Human Tetanus Immunoglobulin should be used in conjunction with tetanus toxoid to ensure effective immunization. It may interfere with the immune response to live vaccines if given simultaneously or within a short time frame.
Disease Interaction
Use with caution in patients with autoimmune disorders or immunodeficiencies, as their immune response may be compromised.
Drug Interaction
Human Tetanus Immunoglobulin may interact with live vaccines. It is advisable to separate the administration of immunoglobulins and live vaccines by several weeks.
Food Interactions
There are no known food interactions with Human Tetanus Immunoglobulin . Patients can maintain a normal diet.
Pregnancy Use
Human Tetanus Immunoglobulin is generally considered safe during pregnancy. It is used when indicated to protect both the mother and fetus from tetanus exposure.
Lactation Use
Human Tetanus Immunoglobulin is also considered safe for use during lactation. It does not affect breastfeeding or the infant adversely.
Acute Overdose
Acute overdose is unlikely due to the controlled dosing of Human Tetanus Immunoglobulin . If an excessive amount is administered, it may lead to increased risk of side effects, such as severe allergic reactions.
Contraindication
Contraindications include:
- Known hypersensitivity to immunoglobulins or any component of the preparation.
- History of severe allergic reactions to previous doses.
Use Direction
Administer Human Tetanus Immunoglobulin intramuscularly as directed by a healthcare provider. Follow the recommended dosage and administration schedule, and ensure it is given promptly after exposure to tetanus or in a tetanus-prone situation.
Storage Conditions
Store Human Tetanus Immunoglobulin in a refrigerator at 2-8°C (36-46°F). Do not freeze. Keep it out of reach of children and protect it from light.
Volume of Distribution
The volume of distribution for immunoglobulins is generally around 5-7 liters in the human body. Specific values for Human Tetanus Immunoglobulin are not typically detailed.
Half Life
The half-life of Human Tetanus Immunoglobulin is approximately 2-3 weeks. This duration may vary based on individual patient factors and response to treatment.
Clearance
Human Tetanus Immunoglobulin is cleared from the bloodstream gradually through the reticuloendothelial system, with the rate of clearance depending on the individual’s metabolism and immune response.
See in details version Human Tetanus Immunoglobulin also Human Tetanus Immunoglobulin in bangla
